Effect of omeprazole on pharmacokinetic parameters of imatinib in rats

ZHAO Zhenhuan; JING Weili; WANG Kai; LYU Zhiqiang; XU Wen

doi:10.6039/j.issn.1001-0408.2023.06.07

您当前的位置：

首页 >

文章列表页 >

Effect of omeprazole on pharmacokinetic parameters of imatinib in rats

更新时间：2023-03-24

- Effect of omeprazole on pharmacokinetic parameters of imatinib in rats
- ZHONGGUO YAOFANG Vol. 34, Issue 6, Pages: 678-681(2023)
- 作者机构：
  
  青岛大学附属医院药学部，山东青岛　266003
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.06.07
  CLC： R969.1;R969.2
- Published：30 March 2023，
  
  Received：22 September 2022，
  
  Revised：04 November 2022，
扫描看全文
赵振寰,荆伟丽,王凯等.奥美拉唑对伊马替尼在大鼠体内药动学参数的影响 ^Δ[J].中国药房,2023,34(06):678-681.

ZHAO Zhenhuan,JING Weili,WANG Kai,et al.Effect of omeprazole on pharmacokinetic parameters of imatinib in rats[J].ZHONGGUO YAOFANG,2023,34(06):678-681.
赵振寰,荆伟丽,王凯等.奥美拉唑对伊马替尼在大鼠体内药动学参数的影响 ^Δ[J].中国药房,2023,34(06):678-681. DOI： 10.6039/j.issn.1001-0408.2023.06.07.

ZHAO Zhenhuan,JING Weili,WANG Kai,et al.Effect of omeprazole on pharmacokinetic parameters of imatinib in rats[J].ZHONGGUO YAOFANG,2023,34(06):678-681. DOI： 10.6039/j.issn.1001-0408.2023.06.07.

摘要

目的

探讨奥美拉唑对伊马替尼在大鼠体内药动学参数的影响。

方法

将大鼠按体质量分为伊马替尼+低、中、高剂量奥美拉唑组和伊马替尼组，每组6只。各组分别按1.8、3.6、7.2 g/kg的剂量灌胃奥美拉唑混悬液或0.5%羧甲基纤维素钠溶液；1 h后，再按10 mg/kg的剂量灌胃伊马替尼混悬液。分别于灌胃前及灌胃后0.5、1、2、2.5、3、4、5、6、8、12、24、36 h时于眼眶取血100 μL，以伊马替尼-

为内标，采用高效液相色谱-串联质谱法测定大鼠血浆中伊马替尼及其代谢产物

-去甲基伊马替尼的浓度；使用DAS 2.0软件计算两种成分的药动学参数并进行比较。

结果

与伊马替尼组比较，伊马替尼+中剂量奥美拉唑组大鼠血浆中伊马替尼的AUC

0－∞

、AUMC

0－∞

和伊马替尼+高剂量奥美拉唑组大鼠血浆中伊马替尼的

max

、

1/2

、AUC

0－∞

，AUMC

0－∞

均显著升高或延长（

＜0.05）。与伊马替尼组比较，伊马替尼+中剂量奥美拉唑组大鼠血浆中

-去甲基伊马替尼的AUC

0－∞

、AUMC

0－∞

和伊马替尼+高剂量奥美拉唑组大鼠血浆中

-去甲基伊马替尼的

max

、AUC

0－∞

均显著降低（

＜0.05）。

结论

奥美拉唑可提高伊马替尼在大鼠体内的血药浓度并降低代谢产物

-去甲基伊马替尼的血药浓度，可能与伊马替尼代谢过程受到抑制有关。

Abstract

OBJECTIVE

To investigate the effects of omeprazole on pharmacokinetic parameters of imatinib in rats.

METHODS

According to body weight， the rats were divided into imatinib+low-dose， medium-dose， and high-dose omeprazole groups， imatinib group， with 6 rats in each group. They were given omeprazole suspension at the doses of 1.8， 3.6 and 7.2 g/kg， or 0.5% sodium carboxymethyl cellulose solution intragastrically respectively； one hour later， imatinib suspension was administered by oral gavage at a the dose of 10 mg/kg. Blood sample （100 μL） was taken from the orbit before and 0.5， 1， 2， 2.5， 3， 4， 5， 6， 8， 12， 24 and 36 hours after intragastric administration of imatinib. Using imatinib-

as internal standard， the plasma concentrations of imatinib and its metabolite

-desmethyl imatinib in rat were determined by high performance liquid chromatography-tandem mass spectrometry. The pharmacokinetic parameters were calculated by DAS 2.0 software and compared.

RESULTS

Compared with imatinib group， AUC

0－∞

and AUMC

0－∞

of imatinib in rat plasma of imatinib+medium-dose omeprazole group，

max

，

1/2

， AUC

0－∞

and AUMC

0－∞

of imatinib in rat plasma of imatinib+high-dose omeprazole group were all increased or prolonged significantly （

＜0.05）. Compared with imatinib group， AUC

0－∞

and AUMC

0－∞

-desmethyl imatinib in rat plasma of imatinib+medium-dose omeprazole group， and

max

and AUC

0→∞

-desmethyl imatinib in rat plasma of imatinib+high-dose omeprazole group were decreased significantly （

＜0.05）.

CONCLUSIONS

Omeprazole may increase the plasma concentration of imatinib in rats and reduce the plasma concentration of

-desmethyl imatinib in rats， which may be associated with inhibiting the metabolism of imatinib.

关键词

奥美拉唑伊马替尼N-去甲基伊马替尼药动学大鼠

Keywords

imatinibN-desmethyl imatinibpharmacokineticsrats

references

ZUIDEMA S，DESAR I M E，VAN ERP N P，et al. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours：a cost-effectiveness study[J]. Br J Clin Pharmacol，2019，85（9）：1994-2001.

LANKHEET N A G，DESAR I M E，MULDER S F，et al. Optimizing the dose in cancer patients treated with imatinib，sunitinib and pazopanib[J]. Br J Clin Pharmacol，2017，83（10）：2195-2204.

张玉，缪丽燕. 胃肠间质瘤靶向药物的治疗药物监测中国专家共识[J]. 中国医院药学杂志，2021，41（20）：2041-2049.

YIN Y，XIANG J，TANG S M，et al. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment[J]. Medicine，2016，95（49）：e5488.

SECRÉTAN，P H，KAROUI M，SADOU-YAYE H，et al. Imatinib：major photocatalytic degradation pathways in aqueous media and the relative toxicity of its transformation products[J]. Sci Total Environ，2019，655：547-556.

PATEL D，BERTZ R，REN S，et al. A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications[J]. Clin Pharmacokinet，2020，59（4）：447-462.

SPARANO B A，EGORIN M J，PARISE R A，et al. Effect of antacid on imatinib absorption[J]. Cancer Chemother Pharmacol，2009，63（3）：525-528.

TAWBI H，CHRISTNER S M，LIN Y，et al. Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers[J]. Cancer Chemother Pharmacol，2014，73（1）：207-211.

EGORIN M J，SHAH D D，CHRISTNER S M，et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib[J]. Br J Clin Pharmacol，2009，68（3）：370-374.

国家药典委员会.中华人民共和国药典：四部[S]. 2020 年版.北京：中国医药科技出版社，2020：466-472.

VAN LEEUWEN R W F，JANSMAN F G A，HUNFELD N G，et al. Tyrosine kinase inhibitors and proton pump inhibitors：an evaluation of treatment options[J]. Clin Pharmacokinet，2017，56（7）：683-688.

NEBOT N，CRETTOL S，D’ESPOSITO F，et al. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes[J]. Br J Pharmacol，2010，161（5）：1059-1069.

GSCHWIND H P，PFAAR U，WALDMEIER F，et al. Metabolism and disposition of imatinib mesylate in healthy volunteers[J]. Drug Metab Dispos，2005，33（10）：1503-1512.

ELBE A，FOERSTER K I，BLANK A，et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans[J]. Eur J Clin Pharmacol，2022，78（6）：975-987.

LIMA J J，THOMAS C D，BARBARINO J，et al. Clinical Pharmacogenetics Implementation Consortium（CPIC）guideline for CYP2C19 and proton pump inhibitor dosing[J]. Clin Pharmacol Ther，2021，109（6）：1417-1423.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats

Study on metabolites derived from Zhideke granules in rats in vivo

Improvement effects of Shangke xiaoyan hydrogel plaster on osteoarthritis model rats

Study on protective effects of twin drugs of tetramethylpyrazine-scutellarein on cerebral ischemia-reperfusion injury model rats and its mechanism

Intervention effect and mechanism of Zhongfeng yure decoction on ischemic stroke model rats

Related Author

ZHENG Huihui

ZHOU Longyue

ZHAO Boxin

WANG Chunxia

LIANG Jie

ZHENG Piaoxue

CHEN Huihua

HUANG Chunyan

Related Institution

Dept. of Pharmacy， Nanfang Hospital of Southern Medical University

Dept. of Pharmacy， Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine

Qinzhou Inspection and Testing Center

Guangxi Zhuang Yao Medicine Engineering Technology Research Center

National Engineering Research Center South China Branch of TCM Solid Preparation Manufacturing Technology

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰